Loading
Leads Japan's national cancer centre, the hub of the country's genomic medicine and early-phase trial programmes.
Hitoshi Nakagama is President of the National Cancer Center Japan, the hub of the country's genomic medicine and early-phase trial programmes. A molecular carcinogenesis researcher, he oversees the centre's hospitals in Tokyo and Kashiwa, its research institute, and national programmes such as SCRUM-Japan and cancer genomic medicine built on comprehensive genomic profiling. His publications include a study of how the tumour-suppressive microRNA miR-34a induces senescence-like growth arrest through the E2F pathway in colon cancer cells, and a review of fatty pancreas as a possible risk factor for pancreatic cancer. His interests span cancer research leadership, prevention and molecular carcinogenesis.
| Title | Journal | Year |
|---|---|---|
| Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells | Proceedings of the National Academy of Sciences | 2007 |
| Fatty pancreas: A possible risk factor for pancreatic cancer in animals and humans | Cancer Science | 2018 |
Shares National Cancer Center Hospital, Comprehensive genomic profiling.
Shares National Cancer Center Hospital, Comprehensive genomic profiling.
Shares National Cancer Center Hospital, Comprehensive genomic profiling.
Shares National Cancer Center Hospital, Comprehensive genomic profiling.
Shares National Cancer Center Hospital, Comprehensive genomic profiling.